ProQR Therapeutics N.V. Stock
Price
Target price
€1.57
€1.57
-4.850%
-0.08
-4.850%
€6.93
12.08.25 / Stuttgart Stock Exchange
WKN: A12B97 / Symbol: PRQR / Name: ProQR / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Loading data...
Your prediction
ProQR Therapeutics N.V. Stock
ProQR Therapeutics N.V. took a tumble today and lost -€0.080 (-4.850%).
We see a rather positive sentiment for ProQR Therapeutics N.V. with 12 Buy predictions and 1 Sell predictions.
With a target price of 6 € there is potential for a 282.41% increase which would mean more than doubling the current price of 1.57 € for ProQR Therapeutics N.V..
Our community identified positive and negative aspects for ProQR Therapeutics N.V. stock for the coming years. 6 users see the criterium "Worthwhile Investment for the next years" as a plus for the ProQR Therapeutics N.V. stock. On the other hand our users think that "Company culture" could be a problem in the future.
Pros and Cons of ProQR Therapeutics N.V. in the next few years
Pros
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
?
S********** s********
Cons
?
G***** c******* t* c**********
?
M***** P*******
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of ProQR Therapeutics N.V. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| ProQR Therapeutics N.V. | -4.850% | -11.356% | -19.908% | -10.751% | -39.280% | 78.742% | -63.681% |
| Pharming Group | -4.220% | -6.625% | 13.302% | 37.377% | 6.006% | -4.625% | -10.220% |
| Ardelyx Inc. | 2.710% | 8.219% | 24.915% | -10.041% | -3.464% | 437.513% | 0.863% |
| Krystal Biotech | 0.800% | 3.665% | -2.957% | -27.081% | -19.152% | 52.857% | - |
Comments
ProQR Therapeutics N.V. (NASDAQ: PRQR) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $4.00 price target on the stock.
Show more
Ratings data for PRQR provided by MarketBeat
ProQR Therapeutics N.V. (NASDAQ: PRQR) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $8.00 price target on the stock.
Show more
Ratings data for PRQR provided by MarketBeat
ProQR Therapeutics (NASDAQ: PRQR) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $15.00 to $9.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for PRQR provided by MarketBeat